
Foresee Pharma announces China NMPA approval of CAMCEVI® 42 mg for treatment of advanced prostate cancer
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNa0pzelJiYWdxTDYwNTFTSGxLU3RnSmhkUnU2QXZpNU9sNUlwNkFWRW52TTZQOUVldHBydUs0bmxwUlhxbE9tekJRNTlhcGM1X2xYalFZOFpYV0Mtd3Z4OVRuNlczYkNMUFVQWnVYbi1CU3J4MVQwcTJDYi11bmUybHZyZjN1M3VzTkNvRDBmb3ZzZU5MdUFySzFETmRaeGViUWt1RjMwWDRKUkhFLVFyMU1wNkpPRGc0dENBY0szUDBLaFUtNDJpU1ZfdTdaeVpKRlJwN1V0aDlYSWl2OWo5OE85cUNabXNBVWc?oc=5" target="_blank">Foresee Pharma announces China NMPA approval of CAMCEVI® 42 mg for treatment of advanced prostate cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">BioSpectrum Asia</font>
